ArticleHealth science reports2025

An Open-Label Phase II Trial of Pembrolizumab, an Immune Checkpoint Inhibitor Alone or in Combination With Oral Azacitidine as Second-Line Therapy for Advanced Head and Neck Squamous Cell Cancers.

Vinod K Ramani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.